Microbix Shareholders Reaffirm Board and Auditor at 2026 Annual Meeting

Microbix Biosystms ( (TSE:MBX) ) has issued an announcement.

Microbix Biosystems Inc., a Canadian life sciences manufacturer, specializes in antigens for immunoassays and laboratory quality assessment products that support clinical diagnostics worldwide. Its QAPs and QUANTDx materials are distributed in more than 30 countries, and the company also advances proprietary therapeutics and diagnostic reagents such as Kinlytic urokinase and DxTM under robust international regulatory accreditations.

Microbix reported that shareholders at its March 25, 2026 annual meeting approved all resolutions, with 27.44% of outstanding shares represented and the full slate of directors re-elected. Investors also backed the re-appointment of Ernst & Young LLP as auditor by a wide margin, signaling continued confidence in the company’s governance and strategic direction, while management’s meeting presentation has been made available online.

The most recent analyst rating on (TSE:MBX) stock is a Hold with a C$0.25 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.

Spark’s Take on MBX Stock

According to Spark, TipRanks’ AI Analyst, MBX is a Neutral.

The score is held down primarily by weakened financial performance (return to losses and negative cash flow) and only mildly supportive technicals (negative MACD and below longer-term averages). The earnings call adds some offset from improving sequential trends, cash collections, and operational initiatives, but near-term revenue/margin uncertainty—especially tied to China—keeps the overall score below average.

To see Spark’s full report on MBX stock, click here.

More about Microbix Biosystms

Microbix Biosystems Inc. is a Canadian life sciences innovator that creates proprietary biological products for human health, generating C$18.6 million in revenue in fiscal 2025. The company supplies critical ingredients and devices for the global diagnostics industry, including antigens for immunoassays and its QAPs and QUANTDx quality assessment and reference materials, which are sold to diagnostics makers, clinical labs, and accreditation bodies in over 30 countries. Microbix also develops other proprietary products such as the Kinlytic urokinase thrombolytic drug and DxTM reagents for molecular diagnostic testing, operating under multiple international quality and regulatory accreditations and listing its shares on the TSX and OTCQX.

Average Trading Volume: 56,454

Technical Sentiment Signal: Sell

Current Market Cap: C$33.25M

See more data about MBX stock on TipRanks’ Stock Analysis page.